Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell recruits deal maker to take over as CEO

Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes
Cancer therapeutics
Dr Holloway's expertise in cancer therapeutics will be invaluable to Scancell

Scancell Holdings PLC (LON:SCLP) has nabbed Dr Cliff Holloway from Benitec Biopharma to be its new chief executive officer, succeeding Dr Richard Goodfellow.

Goodfellow will remain on the board of directors.

READ: Scancell on the lookout for partners after year of “significant progress”

Holloway will seek to drive progress of Scancell's immunotherapy platforms ImmunoBody and Moditope and oversee their commercialisation, the company said.

Holloway was previously chief business and operating officer at Benitec, and before that was chief executive officer of Sienna Cancer Diagnostics.

John Chiplin, executive chairman of Scancell, paid tribute to Goodfellow, saying if it wasn't for his significant achievements, Scancell would not be in the position it's in today.

“We are about to embark on a Phase 2 checkpoint inhibitor combination study with our ImmunoBody vaccine, SCIB1, in melanoma; and our lead Moditope, Modi-1, is progressing rapidly towards the clinic. I would like to thank Richard wholeheartedly for his hard work and substantial contribution to the business, and look forward to continue working alongside him on the board of directors,” Chiplin said.

READ: Scancell presents Moditope data at prestigious cancer conference

Dr Goodfellow said the appointment of Dr Holloway would ensure that Scancell has “a leader with the right mix of skills to guide the company into its next phase of growth”.

“Cliff is an experienced deal maker, which combined with his deep understanding of the science makes him an ideal choice for the job. I have known Cliff for over 10 years and very much look forward to supporting him in his new position," Dr Goodfellow said.

Shares in Scancell were down 1.1% at 12.36p in early deals.

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Newswire
January 31 2017

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use